NYSEAMERICAN:IBIO iBio - IBIO Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding iBio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $1.37 +0.45 (+48.91%) (As of 02/7/2023 12:00 AM ET) Add Compare Share Share Today's Range$0.88▼$1.4950-Day Range N/A52-Week Range$0.36▼$16.51Volume8.30 million shsAverage Volume1.25 million shsMarket Capitalization$12.34 millionP/E RatioN/ADividend YieldN/APrice Target$37.50 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media iBio MarketRank™ ForecastAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside2,637.2% Upside$37.50 Price TargetShort InterestBearish15.76% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.57 out of 5 stars 3.3 Analyst's Opinion Consensus RatingiBio has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $37.50, iBio has a forecasted upside of 2,637.2% from its current price of $1.37.Amount of Analyst CoverageiBio has received no research coverage in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted15.76% of the float of iBio has been sold short.Short Interest Ratio / Days to CoveriBio has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in iBio has recently increased by 50.00%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldiBio does not currently pay a dividend.Dividend GrowthiBio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for IBIO. Previous Next 1.1 News and Social Media Coverage Search Interest34 people have searched for IBIO on MarketBeat in the last 30 days. This is an increase of 55% compared to the previous 30 days.MarketBeat Follows9 people have added iBio to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, iBio insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.38% of the stock of iBio is held by insiders. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of iBio is -0.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of iBio is -0.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioiBio has a P/B Ratio of 0.19. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About iBio (NYSEAMERICAN:IBIO) StockiBio, Inc. is a biotechnology company, which engages in the development and manufacture of biotherapeutics. It operates through the Biopharmaceuticals and Bioprocessing segments. The Biopharmaceuticals segment involves molecule discovery, development, and licensing activities. The Bioprocessing segment includes contract development and manufacturing services for recombinant proteins. The company was founded on April 17, 2008 and is headquartered in Bryan, TX.Read More Receive IBIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for iBio and its competitors with MarketBeat's FREE daily newsletter. Email Address IBIO Stock News HeadlinesJanuary 5, 2023 | finance.yahoo.comiBio Announces Issuance of U.S. Patent Covering AI-Engineered Epitope Discovery EngineJanuary 2, 2023 | marketwatch.comWith 7% CAGR, Hereditary Angioedema Market 2023-2028 Find Out Essential Strategies To Expand The Business And Top Key Players | 93 Pages ReportFebruary 8, 2023 | Wall Street Watch Dogs (Ad)The #1 Energy Stock to BuyThe next major energy revolution is unfolding right now. And it could hand early investors as much as 46,700% gains…December 17, 2022 | marketwatch.comiBio Inc. stock falls Thursday, underperforms marketDecember 17, 2022 | marketwatch.comiBio Inc. stock falls Thursday, underperforms marketDecember 9, 2022 | finance.yahoo.comiBio Announces Closing of $3.5 Million Underwritten Public OfferingDecember 7, 2022 | finance.yahoo.comiBio Announces Pricing of $3.5 Million Underwritten Public OfferingDecember 6, 2022 | finance.yahoo.comiBio Announces Proposed Underwritten Public OfferingFebruary 8, 2023 | Wall Street Watch Dogs (Ad)The #1 Energy Stock to BuyThe next major energy revolution is unfolding right now. And it could hand early investors as much as 46,700% gains…December 6, 2022 | finance.yahoo.comiBio to Participate in the JMP Securities Hematology and Oncology SummitDecember 5, 2022 | finance.yahoo.comiBio® to Showcase the RubrYc® Discovery Engine During Poster Presentations at Antibody Engineering & Therapeutics Conference 2022December 3, 2022 | finance.yahoo.comiBio Announces CEO DepartureNovember 3, 2022 | finance.yahoo.comiBio Accelerates Transformation to AI-Powered BiotechOctober 31, 2022 | finance.yahoo.comiBio, Inc. (IBIO)October 19, 2022 | investorplace.com7 Short-Squeeze Stocks to Sell Before Traders Cash Out - InvestorPlaceOctober 11, 2022 | uk.investing.comWhy ForgeRock Shares Are Trading Higher By Over 49%, Here Are 50 Stocks Moving In Tuesday's Mid-Day Session By Benzinga - Investing.com UKOctober 10, 2022 | benzinga.comStocks That Hit 52-Week Lows On Monday - Teradyne (NASDAQ:TER), Teleflex (NYSE:TFX) - BenzingaOctober 7, 2022 | ft.comCamilla George: Ibio-Ibio album review — Sixties modernism with a west African-slant - Financial TimesSeptember 30, 2022 | investorplace.com3 Healthcare Stocks to Sell Before They Die - InvestorPlaceSeptember 28, 2022 | investing.comIbio Earnings, Revenue Miss in Q1 By Investing.com - Investing.comSeptember 28, 2022 | seekingalpha.comiBio is right to move away from COVID-19 vaccine development - CantorSeptember 28, 2022 | ca.investing.comIbio Earnings, Revenue miss in Q1 By Investing.com - Investing.com CanadaSeptember 28, 2022 | finance.yahoo.comEdited Transcript of IBIO.A earnings conference call or presentation 27-Sep-22 8:30pm GMTSeptember 28, 2022 | au.investing.comIbio Earnings, Revenue miss in Q1 By Investing.com - Investing.com AustraliaSeptember 28, 2022 | in.investing.comIbio earnings, Revenue miss in Q1 - Investing.com IndiaSeptember 27, 2022 | benzinga.comiBio shares are trading lower after the company reported FY22 preliminary sales results and announced a 1 - BenzingaSeptember 27, 2022 | seekingalpha.comiBio reports FY results (NYSE:IBIO) - Seeking AlphaSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive IBIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for iBio and its competitors with MarketBeat's FREE daily newsletter. Email Address IBIO Company Calendar Last Earnings11/15/2021Today2/08/2023Fiscal Year End6/30/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEAMERICAN Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNYSEAMERICAN:IBIO Previous SymbolNASDAQ:IBIO CUSIPN/A CIK1420720 Webwww.ibioinc.com Phone(979) 446-0027Fax302-356-1173Employees49Year FoundedN/APrice Target and Rating Average Stock Price Forecast$37.50 High Stock Price Forecast$37.50 Low Stock Price Forecast$37.50 Forecasted Upside/Downside+2,637.2%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($3.75) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-50,300,000.00 Net Margins-2,004.10% Pretax Margin-2,290.21% Return on Equity-74.73% Return on Assets-49.47% Debt Debt-to-Equity Ratio0.01 Current Ratio1.97 Quick Ratio1.97 Sales & Book Value Annual Sales$2.38 million Price / Sales5.19 Cash FlowN/A Price / Cash FlowN/A Book Value$7.27 per share Price / Book0.19Miscellaneous Outstanding Shares9,010,000Free Float8,793,000Market Cap$12.34 million OptionableNot Optionable Beta-3.15 Key ExecutivesMartin B. BrennerChief Executive & Scientific OfficerMike JenkinsVice President-OperationsRobert M. LutzChief Financial & Business OfficerPhan DillonVice President, Head-Research & DevelopmentMatthew LuterVice President-Information TechnologyKey CompetitorsOncoSec MedicalNASDAQ:ONCSBenitec BiopharmaNASDAQ:BNTCAvenue TherapeuticsNASDAQ:ATXIEarth Science TechOTCMKTS:ETSTEnveric BiosciencesNASDAQ:ENVBView All CompetitorsInsiders & InstitutionsSimplex Trading LLCBought 18,800 shares on 2/2/2023Ownership: 0.000%Vanguard Group Inc.Bought 829,836 shares on 11/15/2022Ownership: 131.952%BlackRock Inc.Bought 2,838,918 shares on 11/15/2022Ownership: 75.468%Renaissance Technologies LLCBought 136,450 shares on 11/14/2022Ownership: 14.298%Ergoteles LLCSold 193,324 shares on 11/14/2022Ownership: 9.275%View All Insider TransactionsView All Institutional Transactions IBIO Stock - Frequently Asked Questions Should I buy or sell iBio stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for iBio in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" IBIO shares. View IBIO analyst ratings or view top-rated stocks. What is iBio's stock price forecast for 2023? 2 analysts have issued 1 year target prices for iBio's stock. Their IBIO share price forecasts range from $37.50 to $37.50. On average, they anticipate the company's stock price to reach $37.50 in the next twelve months. This suggests a possible upside of 2,637.2% from the stock's current price. View analysts price targets for IBIO or view top-rated stocks among Wall Street analysts. Are investors shorting iBio? iBio saw a increase in short interest in December. As of December 30th, there was short interest totaling 1,080,000 shares, an increase of 18.2% from the December 15th total of 913,500 shares. Based on an average trading volume of 445,400 shares, the days-to-cover ratio is presently 2.4 days. Approximately 10.5% of the shares of the stock are sold short. View iBio's Short Interest. How were iBio's earnings last quarter? iBio, Inc. (NYSEAMERICAN:IBIO) announced its quarterly earnings data on Monday, November, 15th. The biotechnology company reported ($1.00) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.25) by $0.25. The biotechnology company had revenue of $0.21 million for the quarter. iBio had a negative trailing twelve-month return on equity of 74.73% and a negative net margin of 2,004.10%. When did iBio's stock split? Shares of iBio reverse split before market open on Tuesday, October 11th 2022. The 1-25 reverse split was announced on Tuesday, October 11th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, October 11th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. What other stocks do shareholders of iBio own? Based on aggregate information from My MarketBeat watchlists, some companies that other iBio investors own include Inovio Pharmaceuticals (INO), Vaxart (VXRT), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Heat Biologics (HTBX), Novavax (NVAX), Dynavax Technologies (DVAX), Co-Diagnostics (CODX), Nokia Oyj (NOK) and Moderna (MRNA). What is iBio's stock symbol? iBio trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "IBIO." Who are iBio's major shareholders? iBio's stock is owned by many different institutional and retail investors. Top institutional shareholders include Simplex Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Eastern Capital Ltd, James P Mullaney, Robert L Erwin and Robert Matthew Lutz. View institutional ownership trends. How do I buy shares of iBio? Shares of IBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is iBio's stock price today? One share of IBIO stock can currently be purchased for approximately $1.37. How much money does iBio make? iBio (NYSEAMERICAN:IBIO) has a market capitalization of $12.34 million and generates $2.38 million in revenue each year. The biotechnology company earns $-50,300,000.00 in net income (profit) each year or ($3.75) on an earnings per share basis. How can I contact iBio? iBio's mailing address is 600 Madison Ave Ste 1601, NEW YORK, NY 10022-1737, United States. The official website for the company is www.ibioinc.com. The biotechnology company can be reached via phone at (979) 446-0027, via email at ir@ibioinc.com, or via fax at 302-356-1173. This page (NYSEAMERICAN:IBIO) was last updated on 2/8/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.